Omicron News and Research

RSS

Broadness of neutralizing antibodies to sarbecoviruses depends on priming conditions

In a recent study under review at the Nature Portfolio journal and currently available on the Research Square* preprint server, researchers identified immune priming conditions that generated broadly neutralizing antibody (nAb) responses and assessed immunity post-third dose of coronavirus disease 2019 (COVID-19) vaccines such as BNT126b2 or Coronavac vaccines after two homologous doses of BNT126b2 or Coronavac vaccines.

7 Jul 2022

TRIM7 inhibits coxsackievirus and norovirus infection

In a recent study posted to the bioRxiv* preprint server, researchers elucidated the underlying mechanisms of tripartite motif containing 7 (TRIM7) activity against coxsackievirus and norovirus.

7 Jul 2022

SARS-CoV-2 RBD vulnerability discovered - target for antibodies against variants

A new study successfully identified a potent neutralization epitope in SARS-related coronaviruses.

6 Jul 2022

Scientists explore mutations in the SARS-CoV-2 receptor-binding domain

Researchers assessed the different mutations of concern in the SARS-CoV-2 receptor-binding domain.

6 Jul 2022

Omicron infections have similar incubation periods but shorter generation intervals than Delta infections

Researchers assessed the differences between the generation-interval distributions and incubation periods of the SARS-CoV-2 Delta and Omicron variants.

6 Jul 2022

Researchers reveal the exceptional capacity of Omicron to evade the immune system

The current wave of COVID-19 highlights a particularly high risk of reinfection by the Omicron variant of SARS-CoV-2.

6 Jul 2022

The host cell membrane binding surfaces of SARS-CoV-2 spike variants

Researchers identified SARS-CoV-2 spike surfaces involved in binding to host cell membranes.

6 Jul 2022

Evaluation of antinucleocapsid antibody seropositivity following SARS-CoV-2 infection in vaccinated individuals

A new study assessed both placebo and vaccine recipients in the mRNA-1273 (Moderna) phase 3 clinical trial who were infected with SARS-CoV-2 during the blinded, placebo-controlled trial phase.

6 Jul 2022

Latest omicron subvariants are better at eluding vaccines and antibody treatments

The latest omicron subvariants - including the BA.4 and BA.5 forms causing new surges in infections in the United States - are even better at eluding vaccines and most antibody treatments than previous variants, finds a study by researchers at Columbia University Vagelos College of Physicians and Surgeons.

5 Jul 2022

SARS-Cov-2 Omicron variant raises significant concerns about high transmissibility in China

Omicron (B.1.1.529), the fifth variant of concern (VOC) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was firstly identified in November 2021 in South Africa. Omicron contains far more genome mutations than any other VOCs ever found, raising significant concerns about its increased transmissibility and immune evasion.

5 Jul 2022

Next-generation SARS-CoV-2 nucleocapsid-based vaccines may provide optimal protection against infection

In a new study,researchers suggested the inclusion of nucleocapsid protein in vaccines against SARS-CoV-2.

5 Jul 2022

Researchers explore long-term pulmonary sequelae of SARS-CoV-2 infection in the pediatric population

Researchers described the long-term pulmonary sequelae of COVID-19 in the pediatric population.

5 Jul 2022

The dynamics of Delta and Omicron establishment and dominance in US states

Researchers analyzed the SARS-CoV-2 Delta and the Omicron VOCs establishment and predominance dynamics in the US.

5 Jul 2022

Effectiveness of two and three doses of BNT162b2 against hospital and ED admissions for BA.1 and BA.2 infection

Researchers compared the effectiveness of two and three-dose regimens of COVID-19 vaccine BNT1262b against Omicron BA.1 and BA.2-related hospital and ED admissions.

5 Jul 2022

How Pfizer won the pandemic, reaping outsize profit and influence

The grinding two-plus years of the pandemic have yielded outsize benefits for one company — Pfizer — making it both highly influential and hugely profitable as covid-19 continues to infect tens of thousands of people and kill hundreds each day.

5 Jul 2022

Study finds hospitalizations for COVID-19–related croup increased after the onset of the Omicron variant

Researchers assessed whether croup infections among young children in the United States were associated with the emergence of new SARS-CoV-2 variants of concern Omicron.

5 Jul 2022

The evolution of COVID-19 epidemiology in Italy over the first two years of the pandemic

A recent study assessed the SARS-CoV-2 lethality and severity during the two years of the SARS-CoV-2 pandemic in Italy.

5 Jul 2022

The influence of immunosuppressive therapy on the development of adaptive immunity after SARS-CoV-2 vaccination

Researchers evaluated the impact of immunosuppressive therapies on the induction of adaptive immunity after COVID-19 vaccination.

5 Jul 2022

The varying patterns of acute respiratory infection hospitalizations before and during two pandemic years

Investigators analyzed the varying pattern of respiratory viruses resulting in hospitalizations from 2012-2013 to 2021-2022 in Canada.

5 Jul 2022

Patient-derived antibody cocktail active across SARS-CoV-2 variants of concern

In a recent study published in the journal Science Immunology, researchers in the United States described a rare anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) three antibody cocktail IMM-BCP-01.

4 Jul 2022

Omicron News and Research

Broadness of neutralizing antibodies to sarbecoviruses depends on priming conditions

TRIM7 inhibits coxsackievirus and norovirus infection

SARS-CoV-2 RBD vulnerability discovered - target for antibodies against variants

Scientists explore mutations in the SARS-CoV-2 receptor-binding domain

Omicron infections have similar incubation periods but shorter generation intervals than Delta infections

Researchers reveal the exceptional capacity of Omicron to evade the immune system

The host cell membrane binding surfaces of SARS-CoV-2 spike variants

Evaluation of antinucleocapsid antibody seropositivity following SARS-CoV-2 infection in vaccinated individuals

Latest omicron subvariants are better at eluding vaccines and antibody treatments

SARS-Cov-2 Omicron variant raises significant concerns about high transmissibility in China

Next-generation SARS-CoV-2 nucleocapsid-based vaccines may provide optimal protection against infection

Researchers explore long-term pulmonary sequelae of SARS-CoV-2 infection in the pediatric population

The dynamics of Delta and Omicron establishment and dominance in US states

Effectiveness of two and three doses of BNT162b2 against hospital and ED admissions for BA.1 and BA.2 infection

How Pfizer won the pandemic, reaping outsize profit and influence

Study finds hospitalizations for COVID-19–related croup increased after the onset of the Omicron variant

The evolution of COVID-19 epidemiology in Italy over the first two years of the pandemic

The influence of immunosuppressive therapy on the development of adaptive immunity after SARS-CoV-2 vaccination

The varying patterns of acute respiratory infection hospitalizations before and during two pandemic years

Patient-derived antibody cocktail active across SARS-CoV-2 variants of concern

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News